Cover Image
市場調查報告書

酒精成癮(酒精中毒):開發平台分析

Alcohol Addiction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213101
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
酒精成癮(酒精中毒):開發平台分析 Alcohol Addiction - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 138 Pages
簡介

所謂酒精成癮(酒精中毒)是指心理性·肉體性對酒精的依賴狀態。主要的症狀有社會活動的參與度低和憂鬱症,不安狀態,無法克制飲酒的欲望,暴力行為等。

本報告提供全球各國治療酒精成癮(酒精中毒)用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

酒精成癮(酒精中毒)概要

治療藥的開發

  • 酒精成癮(酒精中毒)開發中產品:概要
  • 酒精成癮(酒精中毒)開發中產品:比較分析

各企業正在開發的酒精成癮(酒精中毒)治療藥

大學/研究機關研究中的酒精成癮(酒精中毒)治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

酒精成癮(酒精中毒)治療藥:開發中的產品一覽(各企業)

按酒精成癮(酒精中毒)治療藥:研究中的產品一覽(大學/研究機關)

酒精成癮(酒精中毒)開發治療藥的企業

酒精成癮(酒精中毒):治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

酒精成癮(酒精中毒)治療藥:開發中產品的最新趨勢

酒精成癮(酒精中毒)治療藥:開發暫停的產品

酒精成癮(酒精中毒)治療藥:開發中止的產品

酒精成癮(酒精中毒)相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8298IDB

Summary

Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H2 2016', provides an overview of the Alcohol Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
  • The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alcohol Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Alcohol Addiction - Overview
    • Pipeline Products for Alcohol Addiction - Comparative Analysis
  • Alcohol Addiction - Therapeutics under Development by Companies
  • Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes
  • Alcohol Addiction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Alcohol Addiction - Products under Development by Companies
  • Alcohol Addiction - Products under Investigation by Universities/Institutes
  • Alcohol Addiction - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Adial Pharmaceuticals, LLC
    • Astraea Therapeutics, LLC
    • AstraZeneca Plc
    • Bionex Pharmaceuticals LLC
    • Bioprojet SCR
    • Cerecor Inc.
    • Curemark, LLC
    • Eli Lilly and Company
    • Ethypharm S.A.
    • Euthymics Bioscience, Inc.
    • H. Lundbeck A/S
    • Heptares Therapeutics Limited
    • Indivior Plc
    • Johnson & Johnson
    • Kinnov Therapeutics SAS
    • Kyorin Pharmaceutical Co., Ltd.
    • Lohocla Research Corporation
    • Omeros Corporation
    • Pfizer Inc.
    • SK Biopharmaceuticals Co., Ltd.
    • Tonix Pharmaceuticals Holding Corp.
    • VM Discovery, Inc.
    • XenoPort, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Alcohol Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (disulfiram + selegiline) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-705253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABT-436 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amitifadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbaclofen placarbil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baclofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carisbamate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CERC-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-1212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gabapentin enacarbil ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GET-73 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDTic - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-5234801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nalmefene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • odelepran hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05190457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pitolisant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saracatinib difumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-10406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Alcohol Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMD-2202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alcohol Addiction - Dormant Projects
  • Alcohol Addiction - Discontinued Products
  • Alcohol Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
      • May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
      • Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
      • Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
      • Oct 13, 2015: Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
      • Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director
      • Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence
      • Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder
      • Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
      • Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder
      • Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder
      • Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro
      • Nov 26, 2014: Drug recommended to help cut drink dependence
      • Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
      • Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Alcohol Addiction, H2 2016
  • Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Alcohol Addiction - Pipeline by AbbVie Inc., H2 2016
  • Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2016
  • Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016
  • Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2016
  • Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2016
  • Alcohol Addiction - Pipeline by Bioprojet SCR, H2 2016
  • Alcohol Addiction - Pipeline by Cerecor Inc., H2 2016
  • Alcohol Addiction - Pipeline by Curemark, LLC, H2 2016
  • Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2016
  • Alcohol Addiction - Pipeline by Ethypharm S.A., H2 2016
  • Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2016
  • Alcohol Addiction - Pipeline by H. Lundbeck A/S, H2 2016
  • Alcohol Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Alcohol Addiction - Pipeline by Indivior Plc, H2 2016
  • Alcohol Addiction - Pipeline by Johnson & Johnson, H2 2016
  • Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H2 2016
  • Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Alcohol Addiction - Pipeline by Lohocla Research Corporation, H2 2016
  • Alcohol Addiction - Pipeline by Omeros Corporation, H2 2016
  • Alcohol Addiction - Pipeline by Pfizer Inc., H2 2016
  • Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Alcohol Addiction - Pipeline by VM Discovery, Inc., H2 2016
  • Alcohol Addiction - Pipeline by XenoPort, Inc., H2 2016
  • Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Alcohol Addiction - Dormant Projects, H2 2016
  • Alcohol Addiction - Dormant Projects (Contd..1), H2 2016
  • Alcohol Addiction - Dormant Projects (Contd..2), H2 2016
  • Alcohol Addiction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Alcohol Addiction, H2 2016
  • Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top